We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The PAC- SYM questionnaire for chronic constipation: defining the minimal important difference.
- Authors
Yiannakou, Y.; Tack, J.; Piessevaux, H.; Dubois, D.; Quigley, E. M. M.; Ke, M. Y.; Da Silva, S.; Joseph, A.; Kerstens, R.
- Abstract
Background The Patient Assessment of Constipation-Symptoms ( PAC- SYM) questionnaire is frequently used in clinical trials of constipation. However, the threshold for reduction in total PAC- SYM score used to define a clinical response on this 0-4 point scale has not undergone formal appraisal, and its relationship with clinical benefit as perceived by patients has not been defined. Aim To determine the minimal important difference in PAC- SYM score, and the optimum cut-off value for defining responders. Methods The minimal important difference was estimated using data from six international phase 3/4, double-blind, randomised controlled trials of prucalopride in patients with chronic constipation ( NCT01147926, NCT01424228, NCT01116206, NCT00485940, NCT00483886, NCT00488137), with anchor- and distribution-based approaches. Five appropriate patient-reported outcomes were selected as anchors. In addition, receiver operating characteristics ( ROC) curve analyses were used to investigate responder discrimination for each anchor. Results Data from 2884 patients were included. Minimal important difference estimates ranged from -0.52 to -0.63 across the five anchors. Estimates were not affected by study location but were consistently lower for rectal symptoms than for abdominal and stool symptoms. Distribution-based estimates were considerably lower than anchor-based estimates. ROC curve analyses showed optimum cut-off scores for discriminating responders to be similar to anchor-based minimal important difference estimates. Conclusions Anchor-based methods gave consistent results for the minimal important difference, at approximately -0.6, and this value was close to the ROC-determined optimal cut-off scores for responder discrimination. This value could be considered in clinical practice. A slightly more conservative threshold (eg -0.75) could be used in clinical trials to reduce the placebo response rate.
- Subjects
CONSTIPATION; CHRONIC diseases; SYMPTOMS; CLINICAL trials; PLACEBOS
- Publication
Alimentary Pharmacology & Therapeutics, 2017, Vol 46, Issue 11/12, p1103
- ISSN
0269-2813
- Publication type
Article
- DOI
10.1111/apt.14349